Debate โ€บ Ethics ยท Last reviewed 2026-05-16

Ethical criticism

Summary

Ethical criticism of the Dutch Protocol focuses on (i) the capacity of minors to consent to interventions whose long-term effects are partly unknown, (ii) the framing of GnRHa as "fully reversible" diagnostic time, (iii) loss of fertility and sexual function, and (iv) the balance between autonomy and protection in paediatric medicine. See also /protocol/informed-consent/.

1. Capacity

The core question โ€” can adolescents aged 12โ€“16 competently consent to treatment with partly unknown long-term effects โ€” is central in both ethical and legal literature. Levine et al. (2022) argue that the risks of these interventions are ethically managed only through a properly conducted informed consent process, which in practice is limited by erroneous professional assumptions, poor initial evaluations and incomplete information for patients and parents (source).1 See also /debate/legal-cases/.

2. "Diagnostic space" as a concept

The original argument that GnRHa creates "diagnostic time" has been criticised by various authors: GnRHa treatment functionally already starts gender transition, and the continuation rates to cross-sex hormones (98% in the British early intervention study, 98% and 93% in two Dutch studies; Cass Review) suggest that the "diagnostic" phase is in practice not very optional.2 See /protocol/the-three-phases/ for the phase structure, and /studies/follow-up-studies-overview/ for continuation data.

3. Fertility and sexual function

According to the Dutch Health Council (2026), treatment with GnRH agonists in early puberty in principle leads to infertility in trans girls unless they are willing to stop for a long period, and the effects on fertility and cognition are still insufficiently studied (source). Whether an adolescent of 13โ€“16 years can sufficiently grasp the implications of this is a recurring ethical concern โ€” see also /evaluations/wpath-files-2024/ where Environmental Progress reports internal discussions among WPATH members on this point.

See also

Footnotes

  1. Levine SB, Abbruzzese E, Mason JW. J Sex Marital Ther. 2022;48(7):706โ€“27.
  2. van der Loos MATC, et al. Continuation of gender-affirming hormones in transgender people starting puberty suppression in adolescence: a cohort study in the Netherlands. Lancet Child Adolesc Health. 2022;6(12):869โ€“75.